

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**  
**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2256)**

**APPOINTMENT OF JOINT COMPANY SECRETARY AND  
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND  
8.17 OF THE LISTING RULES**

**I. APPOINTMENT OF JOINT COMPANY SECRETARY**

The board (the “**Board**”) of directors (the “**Directors**”) of Abbisko Cayman Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) hereby announces that Dr. Yu Hongping (“**Dr. Yu**”), an executive Director of the Company, has been appointed as one of the joint company secretaries of the Company (the “**Joint Company Secretary**”) with effect from April 29, 2024, and the company secretary of the Company, Ms. Chan Yin Wah (“**Ms. Chan**”), will continue to serve as the other Joint Company Secretary.

The biographical details of Dr. Yu and Ms. Chan are set out below:

Dr. Yu, aged 56, is a co-founder of the Group. Dr. Yu founded the Group on April 12, 2016 and was appointed as a Director and Senior Vice President, Chemistry on March 28, 2018. Dr. Yu was designated as an executive Director on June 10, 2021 and was re-designated as Chief Scientific Officer in March, 2022.

Dr. Yu worked as a senior research chemist at the Merck Frosst Centre for Therapeutic Research from October 2002 to April 2007, a pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical drugs, vaccines and animal-health products. From April 2007 to February 2012, Dr. Yu served as a Senior Research Investigator I at Novartis Institutes for BioMedical Research Co., Ltd., a pharmaceutical company engaged in the development, manufacture and marketing of branded and generic prescription drugs, APIs, biosimilars and ophthalmic products. From October 2012 to February 2016, Dr. Yu served as the deputy General Manager of medicinal chemistry at Shanghai Hansoh BioMedical Co., Ltd. (formerly known as 上海捷森藥物化學科技有限公司).

Dr. Yu has served as a Director at Abbisko Hong Kong since April 2018 and as a Director at Abbisko Shanghai since April 2016, both of which are wholly-owned subsidiaries of the Company. Dr. Yu obtained his Bachelor’s degree in chemistry and his Master’s degree in science from Tsinghua University in the PRC in July 1991 and March 1994, respectively. He obtained his Doctoral degree in chemistry from the University of British Columbia in Canada in November 2000 and was a postdoctoral research fellow at that university between July 2001 and September 2002.

Ms. Chan is an associate director of SWCS Corporate Services Group (Hong Kong) Limited (“**SWCS**”). Ms. Chan joined SWCS in 2011 and has extensive company secretarial professional experience. Ms. Chan holds a bachelor’s degree in economics and a master’s degree in professional accounting. She is a fellow member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Chan is also a fellow member of the Association of Chartered Certified Accountants.

## **II. WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Pursuant to Rule 8.17 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), an issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that an issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of a company secretary by virtue of his/her academic or professional qualifications or relevant experience.

Dr. Yu currently does not possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. However, the Board considers that Dr. Yu, being the co-founder of the Group and the executive director of the Company, is capable of discharging the functions of a Joint Company Secretary by virtue of his knowledge and experience. Therefore, the Company has applied for, and the Stock Exchange has granted a waiver (the “**Waiver**”) to the Company from strict compliance with the requirements for the qualifications of a company secretary under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of appointment of Dr. Yu as a Joint Company Secretary (the “**Waiver Period**”) on the following conditions:

- (i) Dr. Yu must be assisted by Ms. Chan during the Waiver Period;
- (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and
- (iii) the Company will announce the reasons for, and the details and conditions of the Waiver, and the qualification and experience of both Dr. Yu and Ms. Chan.

Before the end of the Waiver Period, the Company must demonstrate and seek the confirmation from the Stock Exchange that Dr. Yu, having had the benefit of Ms. Chan’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Waiver applies to this appointment only and will be revoked immediately if and when Ms. Chan ceases to be a Joint Company Secretary. The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its welcome to Dr. Yu on his appointment as the Joint Company Secretary.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman of the Board*

Hong Kong, April 29, 2024

*As at the date of this notice, the Board comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive Directors; Ms. Tang Yanmin as a non-executive Director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive Directors.*